Evogene Expands Pharma Collaborations Amid Revenue Decline
Event summary
- Evogene reported a 86% year-over-year revenue decline to $0.3M in Q1 2026, primarily due to lower seed sales from Casterra.
- The company announced three new pharma collaborations, bringing the total to four in this domain.
- AgPlenus discontinued its herbicide development project with Bayer, reverting all assets back to Evogene.
- Evogene raised $3.4M in February 2026 through a warrant inducement agreement with an existing investor.
- Cash position stood at $13.1M as of March 31, 2026, with $2.8M in consolidated cash usage during the quarter.
The big picture
Evogene is pivoting towards execution and expansion of its ChemPass AI™ platform, focusing on pharma and agriculture through collaborations. The company's strategic shift involves winding down non-core subsidiaries and strengthening its core technology. The broader industry trend of AI-driven drug discovery and agchemical innovation positions Evogene to compete in high-growth sectors, though its financial stability remains a critical factor.
What we're watching
- Pipeline Progress
- Whether Evogene can advance its pharmaceutical and ag-chemical pipelines toward key milestones through its strategic partnerships.
- Technological Enhancements
- The pace at which Evogene integrates advanced AI agents into ChemPass AI™ and automates complex scientific workflows.
- Financial Stability
- How Evogene manages its cash position and operating expenses amid declining revenues and increased financing costs.
Related topics